Aripiprazole
Product Images NDC 53808-1101

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 53808-1101). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image For 5mg (Aripiprazole 5mg)

This is a medication named Aripiprazole, which comes in 5mg tablet form. The package includes 30 tablets and it is only available through prescription (RXOnly). The medication was manufactured by AMNEAL and the lot number is LOTAOB-1T-2017-1, and the expiration date is 08-17-2018. It was packaged by the DOH Central Pharmacy in Talianassee, FL 32304. The UPC code is 365162897098.*

FDA Label Image

C103b8f2-figure-01 (Aripiprazole Tablets 1)

FDA Label Image

Fig-1 (Aripiprazole Tablets 2)

This text provides information on the effect of other drugs on Aripiprazole. It lists different types of drugs and their impact on the absorption of Aripiprazole, including CYP inhibitors and inducers, gastric acid blockers, and other drugs such as lorazepam. A chart is also included that shows the fold change and 90% confidence interval of Aripiprazole when combined with these drugs.*

FDA Label Image

Fig-2 (Aripiprazole Tablets 3)

This text appears to be a chart listing the effects of different drugs on the drug Aripiprazole. It includes inhibitors, inducers, and blockers and their corresponding effects on Aripiprazole, as well as a fold change and a percentage chart.*

FDA Label Image

Fig-3 (Aripiprazole Tablets 4)

FDA Label Image

Fig-4 (Aripiprazole Tablets 5)

This seems to be a list of variables related to special populations. It includes comparisons based on metabolizer types, gender, age, hepatic impairment, and renal impairment. It also mentions a fold change and confidence interval related to a drug called Avipiprazole. However, it is not clear what PK, e and M represent, and the numbers at the end do not seem to be properly explained.*

FDA Label Image

Fig-5 (Aripiprazole Tablets 6)

FDA Label Image

Fig-6 (Aripiprazole Tablets 7)

This appears to be a graph comparing the proportion with relapse using Avipiprazole versus placebo, over a period of 182 days starting from randomization. Unfortunately, the text is not completely legible due to missing characters, making it difficult to provide a more detailed description.*

FDA Label Image

01 (Aripiprazole Tablets 8)

FDA Label Image

0102 (Aripiprazole Tablets 9)

The text represents a chart/graph with data on the proportion of subjects who experienced relapse after treatment with Aripiprazole or placebo, over a period of time (in days). The chart shows the number of subjects at risk for each treatment group over time. The text is not available to determine what the study was about or what specifically was being measured.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.